WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017062804) CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2017/062804    International Application No.:    PCT/US2016/056051
Publication Date: 13.04.2017 International Filing Date: 07.10.2016
IPC:
A61K 31/4375 (2006.01), C07D 455/03 (2006.01)
Applicants: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA [US/US]; 220 W. 6th Street, University Services Annex, 4th Floor Tucson, AZ 85721 (US)
Inventors: KHANNA, May; (US).
KHANNA, Rajesh; (US).
GOKHALE, Vijay; (US).
CHAWLA, Reena; (US)
Agent: GOETZ, Robert, A.; (US)
Priority Data:
62/238,182 07.10.2015 US
Title (EN) CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF
(FR) INHIBITEURS DE LA SUMOYLATION DE CRMP2 ET UTILISATIONS ASSOCIÉES
Abstract: front page image
(EN)The present invention provides compounds that can modulate the amount of Nav 1.7 protein, a key protein in pain signaling, that is present in the cellular surface and methods for using such compounds. In particular, compounds of the invention modulate the amount of Nav 1.7 protein on the cellular surface by modulating SUMOylation of CRMP2. Thus, compounds of the invention can be used to treat various clinical conditions associated with the presence and/or activation of Nav 1.7 protein on the cellular surface and/or SUMOylation of CRMP2.
(FR)La présente invention concerne des composés qui peuvent moduler la quantité de protéine Nav 1.7, une protéine clé dans la signalisation de la douleur, qui est présente dans la surface cellulaire et des méthodes d'utilisation de tels composés. En particulier, les composés de l'invention modulent la quantité de protéine Nav 1.7 sur la surface cellulaire par la modulation de la SUMOylation de CRMP2. Ainsi, les composés de l'invention peuvent être utilisés pour traiter divers états pathologiques cliniques associés à la présence et/ou à l'activation de la protéine Nav 1.7 sur la surface cellulaire et/ou à la SUMOylation de CRMP2.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)